SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Contrarian Investing -- Ignore unavailable to you. Want to Upgrade?

To: pcyhuang who wrote (94)9/14/2006 11:15:03 PM
From: pcyhuang  Respond to of 4080
 
MAKT -- Correction:

"Note that in recent years, only twice has the stock such technical configuration when both the RSI (14) and % Williams reach an oversold condition simultaneously: once in May, 06 and the second time is now. Market has a combination of our criterion in contrarian investing: value + capitualted volume."

Note that in recent years, only twice did the stock have such a technical configuration that both the RSI (14) and %Williams (14) reached an oversold condition simultaneously -- once in May '06 and the other time is NOW. MAKT meets our criterion of a timely contrarian invstment -- Value + Capitulated Volume.

pcyhuang



To: pcyhuang who wrote (94)9/18/2006 9:46:06 PM
From: pcyhuang  Read Replies (1) | Respond to of 4080
 
MATK -- Latest Operating Results

"Martek Biosciences of Columbia earned $5.3 million (16 cents a share) in its fiscal third quarter, ended July 31, compared with a loss of $109,000 (zero cents) in the third quarter a year earlier. Revenue increased 78 percent, to $70.4 million. The company attributed the results to increased worldwide sales of DHA and ARA, its nutritional supplements, in infant formula." -- Washington Post

pcyhuang


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News